REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for blood cancer patients after CAR t fails
Disease control CompletedThis study tested a drug called nivolumab in 20 adults with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab helps the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New combo tackles tough lymphoma in early trial
Disease control CompletedThis early-phase study tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New hope for tough lymphoma: targeted pill shows promise in trial
Disease control CompletedThis study tested a drug called zanubrutinib in 65 adults with a hard-to-treat type of lymphoma (DLBCL) that has a specific gene change (CD79B mutation) and has come back or not responded to prior treatment. Participants took the drug as a pill and were monitored for tumor shrink…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 17, 2026 04:11 UTC
-
New hope for lymphoma patients: drug duo shows promise in early trial
Disease control CompletedThis study tested a new combination of drugs (ociperlimab plus tislelizumab or rituximab) in 53 adults with diffuse large B-cell lymphoma that had come back or not responded to prior treatment. The main goals were to check safety and find the best dose. Researchers also looked at…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Can a booster shot for immune cells improve lymphoma treatment?
Disease control CompletedThis early-phase study tested a drug called NT-I7 (a long-acting immune booster) given after standard CAR-T cell therapy in 17 adults with large B-cell lymphoma that had come back or not responded to prior treatments. The main goal was to check safety and find the best dose. Rese…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New drug combo shows promise for tough lymphomas
Disease control CompletedThis early-phase trial tested the safety and best dose of olaparib combined with high-dose chemotherapy in 50 adults with lymphomas that returned or didn't respond to treatment. Participants received the drug combo before a stem cell transplant. The goal was to see if adding olap…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 07, 2026 18:38 UTC